BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24675488)

  • 1. Changes in patterns of practice for prostate cancer radiotherapy in Italy 1995-2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society.
    Pegurri L; Buglione M; Girelli G; Guarnieri A; Meattini I; Ricardi U; Mangoni M; Gabriele P; Bellavita R; Krengli M; Bonetta A; Cagna E; Bunkheila F; Borghesi S; Signor M; Di Marco A; Bertoni F; Stefanacci M; Gatta R; De Bari B; Magrini SM
    Tumori; 2014; 100(1):31-7. PubMed ID: 24675488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
    Zelefsky MJ; Marion C; Fuks Z; Leibel SA
    J Urol; 2003 Nov; 170(5):1828-32. PubMed ID: 14532785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy for early-stage prostate cancer in men under 70 years of age.
    Bellavita R; Scricciolo M; Bini V; Arcidiacono F; Montesi G; Lancellotta V; Zucchetti C; Lupattelli M; Palumbo I; Aristei C
    Tumori; 2016; 102(2):209-16. PubMed ID: 26429649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practice patterns for prostate cancer in nine central and northern Italy radiation oncology centers: a survey including 1759 patients treated during two decades (1980-1998).
    Magrini SM; Bertoni F; Vavassori V; Villa S; Cagna E; Maranzano E; Pertici M; Pradella R; Spediacci MA; Chiavacci A; Ambrosi E; Livi L; Magli A; Bellavita R; Bossi A; Biti G
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1310-9. PubMed ID: 11955744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
    Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors.
    Martinez A; Gonzalez J; Spencer W; Gustafson G; Kestin L; Kearney D; Vicini FA
    J Urol; 2003 Mar; 169(3):974-9; discussion 979-80. PubMed ID: 12576825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of age at diagnosis on overall and disease-free survival in men with prostate cancer following conformal 3D radiation therapy.
    Maggio A; Panaia R; Garibaldi E; Bresciani S; Malinverni G; Stasi M; Gabriele P
    Tumori; 2012 Nov; 98(6):722-7. PubMed ID: 23389358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1053-8. PubMed ID: 17398023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalation for prostate cancer using the three-dimensional conformal dynamic arc technique: analysis of 542 consecutive patients.
    Jereczek-Fossa BA; Vavassori A; Fodor C; Santoro L; Zerini D; Cattani F; Garibaldi C; Cambria R; Fodor A; Boboc GI; Vitolo V; Ivaldi GB; Musi G; de Cobelli O; Orecchia R
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):784-94. PubMed ID: 18191332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Conformal radiotherapy for patients with clinical stage T1-T3 prostate cancer].
    Majewski W; Miszczyk L; Zajusz A
    Przegl Lek; 2004; 61(5):503-8. PubMed ID: 15515815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer.
    Kotecha R; Yamada Y; Pei X; Kollmeier MA; Cox B; Cohen GN; Zaider M; Zelefsky MJ
    Brachytherapy; 2013; 12(1):44-9. PubMed ID: 22831750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond D'Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier.
    Gabriele D; Jereczek-Fossa BA; Krengli M; Garibaldi E; Tessa M; Moro G; Girelli G; Gabriele P;
    Radiat Oncol; 2016 Feb; 11():23. PubMed ID: 26911291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
    J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk stratification system and pattern of relapse in patients treated with adjuvant radiotherapy after radical prostatectomy.
    Levis M; Guarneri A; Giaj Levra N; Spratt DE; Bartoncini S; Munoz F; Trino E; Botticella A; Arcadipane F; Ricardi U
    Tumori; 2016 Jun; 2016(3):323-9. PubMed ID: 27002951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical external beam radiotherapy for prostate cancer in Japan: preliminary results of the changing trends in the Patterns of Care process survey between 1996-1998 and 1999-2001.
    Ogawa K; Nakamura K; Sasaki T; Yamamoto T; Koizumi M; Inoue T; Teshima T;
    Jpn J Clin Oncol; 2004 Mar; 34(3):131-6. PubMed ID: 15078908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.